News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,100 Results
Type
Article (42699)
Company Profile (439)
Press Release (677961)
Multimedia
Podcasts (91)
Webinars (16)
Section
Business (208887)
Career Advice (2025)
Deals (36047)
Drug Delivery (105)
Drug Development (83692)
Employer Resources (173)
FDA (16514)
Job Trends (15132)
News (353182)
Policy (33155)
Tag
Academia (2645)
Accelerated approval (12)
Adcomms (26)
Allergies (98)
Alliances (51105)
ALS (115)
Alzheimer's disease (1503)
Antibody-drug conjugate (ADC) (168)
Approvals (16492)
Artificial intelligence (331)
Autoimmune disease (33)
Automation (19)
Bankruptcy (373)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (124)
Biotechnology (331)
Bladder cancer (99)
Brain cancer (36)
Breast cancer (377)
Cancer (2970)
Cardiovascular disease (227)
Career advice (1695)
Career pathing (30)
CAR-T (194)
CDC (32)
Cell therapy (527)
Cervical cancer (22)
Clinical research (68702)
Collaboration (1071)
Company closure (3)
Compensation (703)
Complete response letters (28)
COVID-19 (2686)
CRISPR (65)
C-suite (344)
Cystic fibrosis (119)
Data (3064)
Decentralized trials (2)
Denatured (31)
Depression (71)
Diabetes (351)
Diagnostics (6486)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (147)
Drug pricing (131)
Drug shortages (29)
Duchenne muscular dystrophy (137)
Earnings (88727)
Editorial (44)
Employer branding (21)
Employer resources (149)
Events (117380)
Executive appointments (874)
FDA (18204)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (977)
Gene editing (143)
Generative AI (23)
Gene therapy (407)
GLP-1 (826)
Government (4595)
Grass and pollen (4)
Guidances (182)
Healthcare (19172)
HIV (42)
Huntington's disease (31)
IgA nephropathy (43)
Immunology and inflammation (164)
Immuno-oncology (9)
Indications (40)
Infectious disease (2862)
Inflammatory bowel disease (156)
Inflation Reduction Act (13)
Influenza (64)
Intellectual property (122)
Interviews (312)
IPO (16875)
IRA (48)
Job creations (3708)
Job search strategy (1436)
Kidney cancer (13)
Labor market (53)
Layoffs (528)
Leadership (20)
Legal (8006)
Liver cancer (80)
Longevity (11)
Lung cancer (416)
Lymphoma (212)
Machine learning (11)
Management (58)
Manufacturing (402)
MASH (95)
Medical device (13616)
Medtech (13621)
Mergers & acquisitions (19894)
Metabolic disorders (888)
Multiple sclerosis (99)
NASH (19)
Neurodegenerative disease (132)
Neuropsychiatric disorders (39)
Neuroscience (2224)
NextGen: Class of 2025 (6759)
Non-profit (4558)
Now hiring (48)
Obesity (452)
Opinion (237)
Ovarian cancer (103)
Pain (113)
Pancreatic cancer (123)
Parkinson's disease (193)
Partnered (22)
Patents (306)
Patient recruitment (171)
Peanut (51)
People (59101)
Pharmaceutical (86)
Pharmacy benefit managers (22)
Phase I (21595)
Phase II (30319)
Phase III (22391)
Pipeline (1672)
Policy (214)
Postmarket research (2601)
Preclinical (9276)
Press Release (67)
Prostate cancer (146)
Psychedelics (44)
Radiopharmaceuticals (272)
Rare diseases (492)
Real estate (6025)
Recruiting (67)
Regulatory (23124)
Reports (50)
Research institute (2422)
Resumes & cover letters (352)
Rett syndrome (9)
RNA editing (10)
RSV (49)
Schizophrenia (94)
Series A (169)
Series B (116)
Service/supplier (11)
Sickle cell disease (66)
Special edition (21)
Spinal muscular atrophy (153)
Sponsored (33)
Startups (3776)
State (2)
Stomach cancer (15)
Supply chain (77)
Tariffs (58)
The Weekly (58)
Vaccines (802)
Venture capital (56)
Weight loss (278)
Women's health (49)
Worklife (17)
Date
Today (87)
Last 7 days (367)
Last 30 days (1860)
Last 365 days (32003)
2025 (17382)
2024 (36302)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (738)
Alabama (67)
Alaska (7)
Arizona (252)
Arkansas (14)
Asia (39661)
Australia (6581)
California (7615)
Canada (2384)
China (696)
Colorado (328)
Connecticut (334)
Delaware (195)
Europe (86736)
Florida (1129)
Georgia (249)
Hawaii (1)
Idaho (59)
Illinois (663)
India (27)
Indiana (365)
Iowa (19)
Japan (232)
Kansas (112)
Kentucky (30)
Louisiana (15)
Maine (64)
Maryland (1049)
Massachusetts (5765)
Michigan (248)
Minnesota (461)
Mississippi (3)
Missouri (91)
Montana (30)
Nebraska (25)
Nevada (81)
New Hampshire (70)
New Jersey (2127)
New Mexico (30)
New York (2124)
North Carolina (1153)
North Dakota (9)
Northern California (3324)
Ohio (240)
Oklahoma (16)
Oregon (38)
Pennsylvania (1635)
Puerto Rico (17)
Rhode Island (37)
South America (1112)
South Carolina (34)
South Dakota (1)
Southern California (2842)
Tennessee (126)
Texas (1150)
United States (28350)
Utah (223)
Virginia (193)
Washington D.C. (74)
Washington State (660)
West Virginia (4)
Wisconsin (70)
721,100 Results for "indaptus therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Indaptus Therapeutics Announces Reverse Stock Split
June 25, 2025
·
6 min read
Press Releases
Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 15, 2025
·
11 min read
Press Releases
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
June 2, 2025
·
7 min read
Press Releases
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 14, 2025
·
3 min read
Pharm Country
Indaptus Therapeutics to Present at the 2024 Jefferies Global Healthcare Conference
Indaptus Therapeutics, Inc. announces that Jeffrey Meckler, Chief Executive Officer, and Roger Waltzman, M.D., M.B.A., Chief Medical Officer, will present a corporate overview at the Jefferies Global Healthcare Conference.
May 30, 2024
·
6 min read
Press Releases
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
May 9, 2025
·
6 min read
Press Releases
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
March 19, 2025
·
7 min read
Press Releases
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
November 22, 2024
·
4 min read
Press Releases
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
January 8, 2025
·
10 min read
Press Releases
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
March 13, 2025
·
15 min read
1 of 72,110
Next
